

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Product and Service (Reagent Kits, Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA), By Applications (Diagnostics, Prognostics, Risk assessment) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-04-11 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Breast Cancer Liquid Biopsy Market Analysis and Insights

The Breast Cancer Liquid Biopsy Market size is anticipated to reach USD 103.03 Million in 2022 and it is projected to reach USD 474.62 Million by 2031, growing at a CAGR of % during the forecast period.

The Global Breast Cancer Liquid Biopsy Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Breast Cancer Liquid Biopsy Market growth, Size report provides a comprehensive analysis of the Healthcare IT industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Breast Cancer Liquid Biopsy Market includes major supplies & Independent Consultants among others.

Global Market Scope and Breast Cancer Liquid Biopsy Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Breast Cancer Liquid Biopsy Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Breast Cancer Liquid Biopsy Market Country Level Analysis

The Global Breast Cancer Liquid Biopsy Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Breast Cancer Liquid Biopsy Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Breast Cancer Liquid Biopsy Market

Some of the other major highlights of the demand for Breast Cancer Liquid Biopsy Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Breast Cancer Liquid Biopsy Market during the forecast period.

Biocept Inc.

F. Hoffmann-La Roche Ltd. (Foundation Medicine Inc.)

Fluxion Biosciences Inc.

Menarini Group (Menarini Silicon Biosystems Inc.)

Myriad Genetics Inc.

NeoGenomics Laboratories Inc.

Qiagen N.V.

Sysmex Corporation

Thermo Fisher Scientific Inc.

Guardant Health Inc.

Market Segmentation

The Global Breast Cancer Liquid Biopsy Market Share, Demand provides the most up-to-date Healthcare IT industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Product and Service

Reagent Kits

Instruments

Services

By Circulating Biomarker

Circulating Tumor Cells

Extracellular Vesicles

Circulating Tumor DNA

By Applications

Diagnostics

Prognostics

Risk assessment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Regions Coverd

North America

U.S.
Canada

Europe

U.K.
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC

China
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa

UAE
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

LATAM

Brazil
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

1	Executive Summary
2	Research Scope & Segmentation
2.1	Research Objectives
2.2	Limitations & Assumptions
2.3	Market Scope & Segmentation
2.4	Currency & Pricing Considered
3	Market Opportunity Assessment
3.1	Emerging Regions / Countries
3.2	Emerging Companies
3.3	Emerging Applications / End Use
4	Market Trends
4.1	Drivers
4.2	Market Warning Factors
4.3	Latest Macro Economic Indicators
4.4	Geopolitical Impact
4.5	Technology Factors
5	Market Assessment
5.1	Porters Five Forces Analysis
5.2	Value Chain Analysis
6	Global Breast Cancer Liquid Biopsy Market Size Analysis
6.1	By Product and Service
6.1.1	Reagent Kits
6.1.2	Instruments
6.1.3	Services
6.2	By Circulating Biomarker
6.2.1	Circulating Tumor Cells
6.2.2	Extracellular Vesicles

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.3 Circulating Tumor DNA
- 6.3 By Applications
 - 6.3.1 Diagnostics
 - 6.3.2 Prognostics
 - 6.3.3 Risk assessment
- 7 North America Market Analysis
 - 7.1 By Product and Service
 - 7.1.1 Reagent Kits
 - 7.1.2 Instruments
 - 7.1.3 Services
 - 7.2 By Circulating Biomarker
 - 7.2.1 Circulating Tumor Cells
 - 7.2.2 Extracellular Vesicles
 - 7.2.3 Circulating Tumor DNA
 - 7.3 By Applications
 - 7.3.1 Diagnostics
 - 7.3.2 Prognostics
 - 7.3.3 Risk assessment
 - 7.3 U.S.
 - 7.4 Canada
- 8 Europe Market Analysis
 - 8.1 By Product and Service
 - 8.1.1 Reagent Kits
 - 8.1.2 Instruments
 - 8.1.3 Services
 - 8.2 By Circulating Biomarker
 - 8.2.1 Circulating Tumor Cells
 - 8.2.2 Extracellular Vesicles
 - 8.2.3 Circulating Tumor DNA
 - 8.3 By Applications
 - 8.3.1 Diagnostics
 - 8.3.2 Prognostics
 - 8.3.3 Risk assessment
 - 8.3 U.K.
 - 8.4 Germany
 - 8.5 France
 - 8.6 Spain
 - 8.7 Italy
 - 8.8 Russia
 - 8.9 Nordic
 - 8.10 Benelux
 - 8.11 Rest of Europe
- 9 APAC Market Analysis
 - 9.1 By Product and Service
 - 9.1.1 Reagent Kits
 - 9.1.2 Instruments
 - 9.1.3 Services

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2 By Circulating Biomarker
 - 9.2.1 Circulating Tumor Cells
 - 9.2.2 Extracellular Vesicles
 - 9.2.3 Circulating Tumor DNA
- 9.3 By Applications
 - 9.3.1 Diagnostics
 - 9.3.2 Prognostics
 - 9.3.3 Risk assessment
- 9.3 China
- 9.4 Korea
- 9.5 Japan
- 9.6 India
- 9.7 Australia
- 9.8 Taiwan
- 9.9 South East Asia
- 9.10 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Product and Service
 - 10.1.1 Reagent Kits
 - 10.1.2 Instruments
 - 10.1.3 Services
 - 10.2 By Circulating Biomarker
 - 10.2.1 Circulating Tumor Cells
 - 10.2.2 Extracellular Vesicles
 - 10.2.3 Circulating Tumor DNA
 - 10.3 By Applications
 - 10.3.1 Diagnostics
 - 10.3.2 Prognostics
 - 10.3.3 Risk assessment
- 10.3 UAE
- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 South Africa
- 10.7 Egypt
- 10.8 Nigeria
- 10.9 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Product and Service
 - 11.1.1 Reagent Kits
 - 11.1.2 Instruments
 - 11.1.3 Services
 - 11.2 By Circulating Biomarker
 - 11.2.1 Circulating Tumor Cells
 - 11.2.2 Extracellular Vesicles
 - 11.2.3 Circulating Tumor DNA
 - 11.3 By Applications
 - 11.3.1 Diagnostics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.2 Prognostics
- 11.3.3 Risk assessment
- 11.3 Brazil
- 11.4 Mexico
- 11.5 Argentina
- 11.6 Chile
- 11.7 Colombia
- 11.8 Rest of LATAM
- 12 Competitive Landscape
- 12.1 Global Breast Cancer Liquid Biopsy Market Share By Players
- 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
- 13.1 American International Industries (GIGI)
- 13.1.1 Overview
- 13.1.2 Business Information
- 13.1.3 Revenue
- 13.1.4 ASP
- 13.1.5 Swot Analysis
- 13.1.6 Recent Developments
- 13.2 F. Hoffmann-La Roche Ltd. (Foundation Medicine Inc.)
- 13.3 Fluxion Biosciences Inc.
- 13.4 Menarini Group (Menarini Silicon Biosystems Inc.)
- 13.5 Myriad Genetics Inc.
- 13.6 NeoGenomics Laboratories Inc.
- 13.7 Qiagen N.V.
- 13.8 Sysmex Corporation
- 13.9 Thermo Fisher Scientific Inc.
- 13.10 Guardant Health Inc.
- 14 Research Methodology
- 14.1 Research Data
- 14.1.1 Secondary Data
- 14.1.1.1 Major secondary sources
- 14.1.1.2 Key data from secondary sources
- 14.1.2 Primary Data
- 14.1.2.1 Key data from primary sources
- 14.1.2.2 Breakdown of primaries
- 14.1.3 Secondary And Primary Research
- 14.1.3.1 Key industry insights
- 14.2 Market Size Estimation
- 14.2.1 Bottom-Up Approach
- 14.2.2 Top-Down Approach
- 14.2.3 Market Projection
- 14.3 Research Assumptions
- 14.3.1 Assumptions
- 14.4 Limitations
- 14.5 Risk Assessment
- 15 Appendix

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1 Discussion Guide
- 15.2 Customization Options
- 15.3 Related Reports
- 16 Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Product and Service (Reagent Kits, Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA), By Applications (Diagnostics, Prognostics, Risk assessment) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-04-11 | 0 pages | Straits Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-02-23

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com